Lasa Supergenerics Limited engages in the research, manufacture, and marketing of animal and human healthcare products primarily in India. It offers API products comprising fenbendazole, toldimphos sodium, cyromazine, albendazole, riclabendazole, rafoxanide, ornidazole, ricobendazole, oxfendazole, closantel base, closantel sodium, nitroxynil, halquinol, and oxyclozanide, as well as 2,6-diiodo-4-nitrophenol; and other API products. The company also provides animal feed ingredients, including calcium iodate; and reagents for therapeutic use comprising potassium iodide. It also exports its products. Lasa Supergenerics Limited was incorporated in 2016 and is based in Ratnagiri, India.
Stock data | 2024 | Change |
---|---|---|
Price | $0.32297437533493806 | N/A |
Market Cap | $16.18M | N/A |
Shares Outstanding | 50.10M | N/A |
Employees | 89.00 | N/A |